MBG453

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

12 competitors in Recurrent

#DrugCompanyPhaseTrials

1

Xiaflex

GGrupo Espanol de Tumores Neuroendocrinos

Approved

12

Certolizumab

Johnson & Johnson

Phase 3

13

Opdivo

Bristol-Myers Squibb

Phase 2

24

Yervoy

Bristol-Myers Squibb

Phase 1

15

Lu-PSMA I&T

MMedical University of Vienna

Phase 2

16

Anti-PD-1 Monoclonal Antibody

IiTeos Therapeutics

Phase 1

17

Photofrin

PPinnacle Biologics Inc.

Preclinical

18

Cordarone

WWyeth-Lederle Vaccines

Preclinical

19

Ptvg-HP

UUniversity of Wisconsin, Madison

Phase 1

110

CART-EGFR-Il13ra2 Cells

UUniversity of Pennsylvania

Phase 1

1Show 1 more competitor

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Myelodysplastic Syndrome2 trials

HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

Terminated·Novartis·Phase 1·NCT03940352·52 enrolled

A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).

Terminated·Novartis·Phase 2·NCT03946670·127 enrolled

MDS2 trials

STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

Terminated·Novartis·Phase 2·NCT04878432·39 enrolled

MBG453 in Lower Risk MDS

Terminated·MMassachusetts General Hospital·Phase 2·NCT04823624·10 enrolled

Recurrent1 trial

Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM

Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT03961971·16 enrolled

Advanced Malignancies1 trial

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Terminated·Novartis·Phase 1/2·NCT02608268·252 enrolled

Myelofibrosis1 trial

Study of Select Combinations in Adults With Myelofibrosis

Withdrawn·Novartis·Phase 1·NCT04283526

3 more indications

Phase IB1 trial

Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS

Terminated·Novartis·Phase 1·NCT04810611·33 enrolled

Chemotherapy1 trial

A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy

Terminated·Novartis·Phase 2·NCT04150029·90 enrolled

High Risk1 trial

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

Completed·Novartis·Phase 1·NCT03066648·241 enrolled

Details

Drug Info

Related News